Dissection of the humoral immune response toward an immunodominant epitope of HIV: A model for the analysis of antibody diversity in HIV+ individuals

FASEB Journal

Volumn 15, Issue 12, 2001, Pages 2112-2120

  Enshell Seijffers, David ^a   Smelyanski, Larisa ^a   Vardinon, Nurith ^b   Yust, Israel ^b   Gershoni, Jonathan M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

AIDS; Humoral response; Peptides; Phage display

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; POLYCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

AMINO ACID SEQUENCE; ANTIBODY DIVERSITY; CONSENSUS SEQUENCE; CROSS REACTIONS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; LONGITUDINAL STUDIES; PEPTIDE LIBRARY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034810895     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0898com     Document Type: Article

References (57)

1. Why do we not have an HIV vaccine and how can we make one?
2. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
3. Varicella-zoster virus
4. Humoral immunity to HIV
5. The antibody response in HIV-1 infection
6. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: Results of a 6 year prospective study
7. Toward an understanding of the correlates of protective immunity to HIV infection
8. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1
9. Passive immune globulin therapy in the SIV/macaque model reduces viremia and delays disease
10. Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile
11. Prevention of HIV infection by passive immunization with HIV immunoglobulin
12. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG
13. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
14. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
15. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary isolate
16. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe
17. Continuous epitopes of the immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates
18. Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies
19. Generation of human monoclonal antibodies to human immunodeficiency virus
20. Production and characterization of human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type 1
21. Human monoclonal antibodies to HIV-1: Cross-reactions with gag and env proteins
22. Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1
23. Searching for peptide ligands with an epitope library
24. Epitope mapping using bacteriophage peptide libraries
25. Epitope discovery using peptide libraries displayed in phage
26. Identification of biologically active peptides using random libraries displayed on phage
27. Tapping the potential of molecular libraries in functional genomics
28. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera
29. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries
30. HIV-1 auxiliary proteins: Making connections in a dying cell
31. Viral subversion of the immune system
32. Genomic diversity and antigenic variation of HIV-1: Link between pathogenesis, epidemiology and vaccine development
33. Mutation drift and repertoire shift in the maturation of the immune response
34. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
35. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies
36. Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape
37. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus
38. B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus
39. Identification of sites within gp41 that serves as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies
40. Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus
41. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies
42. Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody
43. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
44. An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement
45. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera
46. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients
47. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration
48. 'Affinity maturation' of ligands for HCV-specific serum antibodies
49. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants
50. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity
51. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus
52. Immunology taught by viruses
53. How many specific B cells are needed to protect against a virus?
54. Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation
55. Binding of HIV-1 gp120 to an anti-V3 loop antibody reveals novel antigen-induced epitopes
56. Expansion of epitope cross-reactivity by anti-idiotypic modulation of the primary humoral response
57. Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1